Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine-Reference-Cited by-同舟云学术

Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine

Published:2023-04 Issue: Volume:212 Page:105556
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Lu Changrui,Zhang Yuntao,Liu Xiaohu,Hou Fujun,Cai Rujie,Yu Zhibin,Liu Fei,Yang Guohuan,Ding Jun,Xu Jiang,Hua Xianwu,Cheng Xinhua,Pan Xinping,Liu Lianxiao,Lin Kang^ORCID,Wang Zejun,Li Xinguo,Lu Jia,Zhang Qiu,Li Yuwei,Hu Chunxia,Fan Huifen,Liu Xiaoke,Wang Hui,Jia Rui,Xu Fangjingwei,Wang Xuewei,Huang Hongwei,Zhao Ronghua,Li Jing,Cheng Hang,Jia William,Yang Xiaoming

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference63 articles.

1. PHENIX: a comprehensive Python-based system for macromolecular structure solution;Adams;Acta Crystallogr D Biol Crystallogr,2010

2. The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates;Al Kaabi;Sci. Rep.,2022

3. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients;Andreano;Cell,2021

4. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine;Baden;N. Engl. J. Med.,2021

5. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity;Bai;Cell Res.,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up;International Immunopharmacology;2024-06

2. Prevention and treatment of HPV‐related cancer through a mRNA vaccine expressing APC‐targeting antigen;Immunology;2024-03-12

3. Safety and immunogenicity of COReNAPCIN^®, a SARS-CoV-2 mRNA vaccine; a randomized, double-blind, placebo-controlled phase 1 clinical trial;2023-11-02

4. Vaccines’ New Era-RNA Vaccine;Viruses;2023-08-18